Event JSON
{
"id": "2d59a5e37297c6f81bdfa659be6c132967d9b544440327c76bad9ff2bfb369cc",
"pubkey": "21856daf84c2e4e505290eb25e3083b0545b8c03ea97b89831117cff09fadf0d",
"created_at": 1697718352,
"kind": 1,
"tags": [
[
"e",
"aa452d1f213a4649fe068d491d75dbd25906cbe1a65d1fc6e1fa2ff8a87614b8",
"wss://relay.mostr.pub",
"reply"
],
[
"t",
"evergreening"
],
[
"content-warning",
"Long thread/2"
],
[
"proxy",
"https://mamot.fr/users/pluralistic/statuses/111261669977477352",
"activitypub"
]
],
"content": "There's plenty wrong with this argument. For one thing, pharma companies use their monopoly winnings to sell drugs, not invent drugs. For every dollar pharma spends on research, it spends three dollars on marketing:\n\nhttps://www.bu.edu/sph/files/2015/05/Pharmaceutical-Marketing-and-Research-Spending-APHA-21-Oct-01.pdf\n\nAnd that \"R\u0026D\" isn't what you're thinking of, either. Most R\u0026D spending goes to \"#evergreening\" - coming up with minor variations on existing drugs in a bid to extend those patents for years or decades:\n\nhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680578/\n\n2/",
"sig": "bc072b4d8e0a9e3abc1b72d316c4c5f22bec6fd821c056119c49fabeee7e6ac92d592c8a519be27a19c90e530acfd4577e6ed2667b70663c1d0c0da2d02eb189"
}